PILA PHARMA publishes interim report for July 1 - September 30, 2021

PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company's interim report for the period July - September 2021. The report can be found on the Company's website: https://pilapharma.com/investors/finansiell-information/

SUMMARY OF INTERIM REPORT

Nine months (1 January - 30 September 2021)

  • Revenue was SEK 0 (0)
  • Operating loss (EBIT) was SEK - 6 180 (- 1 759) thousand
  • Net loss was SEK - 11 785 (- 1 759) thousand
  • Earnings per share, basic and diluted, were SEK - 0,91 (-0,18)
  • Cashflow was SEK - 31 411 (- 3 726) thousand, whereof from ongoing business was SEK- 7 069 (- 5 210) thousand
  • Cash and cash equivalents were at the end of the period SEK 33 318 (340) thousand
  • Equity amounted to SEK 35 717 (7 182) thousand
  • Solidity was 95% (96%)

Third quarter (1 July - 30 September 2021)

  • Revenue was SEK 0 (0)
  • Operating loss (EBIT) was SEK - 3 174 (-294) thousand
  • Net loss was SEK - 5 577 (-294) thousand
  • Earnings per share, basic and diluted, were SEK - 0,39 (-0,03)
  • Cashflow was SEK 26 926 (250) thousand, whereof from ongoing business was SEK - 3 535 (-203) thousand

Significant events in the third quarter (1 July- 30 September 2021)

  • On July 15, 2021, PILA PHARMA's shares were listed on Nasdaq First North Growth Market in Stockholm. The rights issue was fully booked, and the Company received SEK 31,5 million after costs of the issue that amounted to SEK 3,5 million.
  • The warrant PILA PHARMA TO1 had its trade start on July 22
  • A manufacturing agreement was signed with Almac Sciences for the production of the active pharmaceutical ingredient (API), XEN-D0501, for toxicology studies
  • Kickstart meeting with Almac Sciences and first step to the chemical synthesis
  • GMP-certification of a new batch of placebo tablets to match 4 mg XEN-D0501 for use in upcoming clinical trials

Significant events after the quarter

  • The Nobel prize of 2021 in physiology or medicine was partly given to Dr. David Julius, for his discovery of TRPV1 (the chili receptor) and its role in regulation of pain and temperature. The award is an important scientific acknowledgement of crucial bodily functions, which is especially interesting since PILA PHARMA is developing a treatment of diabetes type 2 through a TRPV1 antagonist.

CEO comment:

"The big event of the first half of 2021 was of course the Nasdaq First North listing on July 15. Moreover, PILA PHARMA has received GMP-certification of a new batch of placebo and 4 mg XEN-D0501 tablets which are to be used in our phase 2 study. I am very pleased with this, as it takes several months to produce tablets. It is a big thing to have this done, since, it is one of two bottlenecks prior to sending in the clinical trial application for the phase 2b study. Now remains to conduct the obligatory toxicology studies, as the final bottleneck. For these studies, several kilos of the XEN-D0501 active substance (API) are required. After an evaluation of potential API manufacturers, we signed an agreement with Almac Sciences Limited, UK, and the cooperation proceeds according to plan. We are also in the final phase of contracting a Contract Research Organization (CRO) for the conduct of the toxicology studies. In parallel to this we are evaluating several clinic CRO's in order to choose the one that in the best way can assist us with the phase 2b study.

Malmö, October 26, 2021
The Board of Directors

This information is such information that PILA PHARMA AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted for publication on October 26, 2021, at 08:00 CET.

For more information:
Dorte X. Gram, VD
SMS: +46 (0)73 903 6969
[email protected]

About PILA PHARMA

PILA PHARMA is a Swedish biotech company in the diabetes segment based in Malmö. The aim of the company is to develop a novel and superior tablet-based treatment for type 2 diabetes. The company owns both use patents for treating diabetes and obesity with TRPV1 antagonists, and the intellectual property rights for the mid stage clinical development candidate XEN-D0501.

About XEN-D0501 and TRPV1 antagonists

XEN-D0501 is a highly selective and very potent small molecule TRPV1 antagonist, previously in development by Bayer Healthcare and Xention/Ario Pharma. The TRPV1 target (also called the "chili-receptor") has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes as well. XEN-D0501 was acquired by PILA PHARMA in March 2016, due to its very good safety and tolerability as compared to other clinical TRPV1-antagonist development candidates. TRPV1 antagonists as a drug-class has previously been associated with severe adverse events as fever (hyperthermia). The maximal tolerable dose in non-diabetic individuals has previously been determined to be 4 milligrams twice daily, a dose level with good safety but no effect in non-diabetic patients with either overactive bladder disease or chronic cough. In November 2018, PILA PHARMA reported the completion of its first clinical trial, PP-CT01, demonstrating good safety of XEN-D0501 at single doses up to 8 milligrams when administered to people with type 2 diabetes. The most recent study results were announced in September 2020. The study (PP-CT02) demonstrated that multiple doses of XEN-D0501 (4 milligrams twice daily for 28 days) were likewise safe and well-tolerated by people with type 2 diabetes and also - with statistical significance versus placebo - that XEN-D0501 enhances the endogenous insulin response to oral glucose, thus demonstrating proof of principle.

About diabetes

Diabetes is a world-wide pandemic with a staggering prevalence of 463 million diabetics corresponding to approximately 8-10% of the population. Approximately 90 % of all diabetics suffer from type 2 diabetes, whilst approximately 10% suffers from type 1 diabetes. The disease can lead to cardiovascular disease resulting in reduction of quality of life for the patient, increased risk of death and high health care expenses. Despite recent therapeutic advances, large and growing unmet needs exist both from an efficacy, safety, adherence, accessibility and affordability perspective.

KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB

Aktieägarna i PILA PHARMA AB, org.nr 556966-4831 ("PILA PHARMA" eller "Bolaget"), kallas härmed till årsstämma tisdagen den 7 juni 2022 kl. 11.00 på Västergatan 1 i Malmö. Registrering till stämman börjar kl. 10.30.


Pila Pharma delårsrapport för 1 januari - 31 mars 2022

PILA PHARMA AB (publ) (FN STO: PILA) publicerar i dag bolagets delårsrapport för perioden januari - mars 2022 som finns att ta del av på bolagets hemsida: https://pilapharma.com/investors/finansiell-information/


PILA PHARMA publishes interim report January 1 - March 31, 2022

PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company's interim report for the period January - March 2021. The report can be found on the Company's website: https://pilapharma.com/investors/finansiell-information/


Pila Pharma AB tillkännager certifiering av API

Pila Pharma AB (PILA) tillkännager i dag att det studieläkemedel (non-GMP API) som ska användas vid tremånadres prekliniska studier har erhållit ett analyscertifikat och därmed är klart att använda.


Pila Pharma AB announces certification of API

Pila Pharma AB (PILA) today announces that the study material (non-GMP API) to be used in three-month preclinical studies has received a certificate of analysis and is thus ready to use.


Pila Pharma bygger pipeline - ansöker om Orphan Drug Designation i USA

Pila Pharma AB meddelar att bolaget har ansökt om Orphan Drug Designation (särläkemedelsstatus) vid U.S. Food and Drug Administration, FDA, för utvecklingskandidaten XEN-D0501. Syftet är att ta fram en behandling av en sjukdom förknippad med smärta på grund av neurogen inflammation.


Pila Pharma builds pipeline - applies for Orphan Drug Designation in the USA

Pila Pharma AB announces that the company has submitted a request for an Orphan Drug Designation to the U.S. Food and Drug Administration (FDA) for the company's development candidate XEN-D0501. The aim is to develop a novel treatment of a rare disease associated with pain due to neurogenic inflammation.


Pila Pharma AB publicerar årsredovisning för 2021

Pila Pharma AB (publ) meddelar att årsredovisningen nu finns tillgänglig på bolagets hemsida, https://pilapharma.com/investors/finansiell-information, samt som bilaga till detta pressmeddelande.


Pila Pharma AB publishes annual report for 2021

Pila Pharma AB (publ) announces that the annual report now is available on the company's homepage, https://pilapharma.com/investors/finansiell-information, and as an attachment to this press release.


Pila Pharma AB:s årsredovisning för 2021 försenas

Pila Pharma AB (publ) meddelar att årsredovisningen för 2021, som skulle publiceras den 22 mars 2022, är försenad och istället kommer att publiceras den 23 mars 2022.


Pila Pharma AB's annual report for 2021 delayed

Pila Pharma AB (publ) announces that the annual report for 2021, which was to be published on March 22, 2022, is delayed and will instead be published on March 23, 2022.


PILA PHARMA AB - VD Dorte X. Gram ökar sitt innehav

PILA PHARMA AB (publ) meddelar att VD Dorte X. Gram under måndagen och tisdagen den 21 och 22 februari köpt 18 878 aktier i bolaget. Aktierna köptes till en snittkurs om 5,39 SEK.


PHARMA AB - CEO Dorte X. Gram increases share holding

PILA PHARMA AB (publ) announces that CEO Dorte X. Gram on Monday and Tuesday, February 21 and 22, bought 18,878 shares in the company. The shares were purchased at an average price of SEK 5.39.


Correction: Missing attached year-end report in previous pressrelease - PILA PHARMA publishes year-end report January 1 - December 31, 2021

Correction: Pressrelease 2022-02-18: In the previous pressrelease the year-end report, for 1 januar - 31 december, was not attached. This is now corrected and the report is attachted to this pressrealease.

PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company's year-end report for the period January - December 2021. The report can also be found on the Company's website: https://pilapharma.com/investors/finansiell-information/


PILA PHARMA bokslutskommuniké för 1 januari - 31 december 2021

PILA PHARMA AB (publ) (FN STO: PILA) publicerar i dag bolagets bokslutskommuniké för perioden januari - december 2021 som finns att ta del av på bolagets hemsida: https://pilapharma.com/investors/finansiell-information/


PILA PHARMA publishes year-end report January 1 - December 31, 2021

PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company's year-end report for the period January - December 2021. The report can be found on the Company's website: https://pilapharma.com/investors/finansiell-information/


PILA PHARMA AB tillkännager milstolpe avseende API-produktion samt ändringar i organisationen

PILA PHARMA AB (PILA) tillkännager i dag att den första milstolpen avseende API-produktion har uppnåtts i sin helhet.


PILA PHARMA AB, announces API manufacturing milestone achieved and changes to organisation

PILA PHARMA AB (PILA) today announces their first API manufacturing milestone has been successfully achieved.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted